Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Lifecore Biomedical Inc. (LFCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LFCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 30.09% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 260.66M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 187576 | Beta 0.97 | 52 Weeks Range 3.68 - 7.99 | Updated Date 04/1/2025 |
52 Weeks Range 3.68 - 7.99 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.89% | Operating Margin (TTM) -4.78% |
Management Effectiveness
Return on Assets (TTM) -2.47% | Return on Equity (TTM) -29.58% |
Valuation
Trailing PE - | Forward PE 8.67 | Enterprise Value 382913583 | Price to Sales(TTM) 1.99 |
Enterprise Value 382913583 | Price to Sales(TTM) 1.99 | ||
Enterprise Value to Revenue 2.93 | Enterprise Value to EBITDA 25.61 | Shares Outstanding 37025300 | Shares Floating 20094758 |
Shares Outstanding 37025300 | Shares Floating 20094758 | ||
Percent Insiders 4.52 | Percent Institutions 73.6 |
Analyst Ratings
Rating 3.67 | Target Price 8.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lifecore Biomedical Inc.
Company Overview
History and Background
Lifecore Biomedical, Inc. was founded in 1964 as Land O'Lakes, Inc. (LOL) Immunobiologics Division. It became a separate entity in 1980 as Medeva, Inc. and later changed its name to Lifecore Biomedical, Inc. It has focused on contract development and manufacturing organization (CDMO) services and hyaluronan-based products.
Core Business Areas
- CDMO Services: Offers contract development and manufacturing services for injectable pharmaceuticals and medical devices, including formulation, fill-finish, and regulatory support.
- Hyaluronan-Based Products: Develops and manufactures hyaluronan-based products for ophthalmic and veterinary applications.
Leadership and Structure
Lifecore Biomedical's leadership team consists of experienced executives in the pharmaceutical and medical device industries. The organizational structure typically includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Hyaluronic Acid (HA) Based Ophthalmic Solutions: Lifecore offers highly purified HA solutions for ophthalmology. Market share data is proprietary, but the market is competitive with Allergan and Bausch + Lomb.
- Injectable Pharmaceuticals CDMO Services: Provides formulation, fill-finish, and testing services for pharmaceutical companies. Market share varies based on specific injectable drug types. Competitors include Recipharm and Catalent.
Market Dynamics
Industry Overview
The pharmaceutical and medical device CDMO industry is experiencing growth driven by increased outsourcing from pharmaceutical companies. The hyaluronan market is driven by demand for ophthalmic and aesthetic applications.
Positioning
Lifecore Biomedical is positioned as a specialized CDMO focusing on complex injectable formulations and high-quality hyaluronan production. The company benefits from its expertise and established regulatory compliance.
Total Addressable Market (TAM)
The global CDMO market is estimated to be over $200 billion. The HA market is projected to reach billions of dollars. Lifecore is focused on specific injectable pharmaceutical and hyaluronan niches within these larger TAMs.
Upturn SWOT Analysis
Strengths
- Specialized expertise in complex injectable formulations
- High-quality hyaluronan production capabilities
- Established regulatory compliance
- Strong relationships with pharmaceutical and medical device companies
Weaknesses
- Relatively smaller size compared to larger CDMOs
- Dependence on a limited number of key customers
- Potential vulnerability to supply chain disruptions
- Limited resources for extensive market expansion
Opportunities
- Growing demand for CDMO services
- Increasing adoption of hyaluronan-based products
- Expansion into new therapeutic areas
- Strategic partnerships and acquisitions
Threats
- Intense competition in the CDMO market
- Regulatory changes affecting pharmaceutical manufacturing
- Economic downturn impacting pharmaceutical spending
- Technological advancements rendering existing products obsolete
Competitors and Market Share
Key Competitors
- Lonza (LONN.SW)
- Catalent (CTLT)
- Recipharm (RECI-B.ST)
Competitive Landscape
Lifecore Biomedical operates in a competitive market with larger, more established players. Its competitive advantage lies in its specialized expertise and high-quality production capabilities. However, it faces challenges related to scale and resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future projections are based on general CDMO growth and HA market growth.
Recent Initiatives: Recent initiatives involve expansion of CDMO manufacturing capacity and development of new HA-based products.
Summary
Lifecore Biomedical is a specialized CDMO and hyaluronan producer operating in growing markets. Its strengths lie in its expertise and quality, but its smaller scale presents challenges. Expansion and strategic partnerships could drive future growth, while competition and economic factors pose threats.
Similar Companies
- CTLT
- LONN.SW
- RECI-B.ST
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- Financial News Sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available industry reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lifecore Biomedical Inc.
Exchange NASDAQ | Headquaters Chaska, MN, United States | ||
IPO Launch date 1996-02-15 | President, CEO & Director Mr. Paul Josephs | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 524 | Website https://www.lifecore.com |
Full time employees 524 | Website https://www.lifecore.com | ||
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.